GSK Secures mRNA Vaccines For Bird Flu, COVID And Seasonal Flu From Struggling Biotech CureVac
Forbes Healthcare
JULY 3, 2024
mRNA specialist CureVac, which struggled to compete with the likes of Pfizer, Moderna and BioNTech, said it will focus on developing mRNA cancer vaccines and will cut 30% of its staff.
Let's personalize your content